Inhibrx Inc

-0.17 (-0.42%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.53B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.71 Million
Adjusted EPS-$0.59
See more estimates
10-Day MA$40.76
50-Day MA$38.79
200-Day MA$28.34
See more pivots

Inhibrx Inc Stock, NASDAQ:INBX

11025 North Torrey Pines Road, Suite 200, La Jolla, California 92037
United States of America
Phone: +1.858.795.4220
Number of Employees: 91


Inhibrx, Inc. is a biotechnology company. It is a clinical stage company, which focuses on developing pipeline of novel biologic therapeutic candidates. The firmâ??s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA.